Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 146 articles:
HTML format



Single Articles


    July 2021
  1. PAN J, Tan Y, Wang G, Deng B, et al
    Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
    J Clin Oncol. 2021 Jul 29:JCO2100389. doi: 10.1200/JCO.21.00389.
    PubMed     Abstract available


  2. STEPHENS DM
    Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    J Clin Oncol. 2021 Jul 26:JCO2101414. doi: 10.1200/JCO.21.01414.
    PubMed    


  3. BYRD JC, Hillmen P, Ghia P, Kater AP, et al
    Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    J Clin Oncol. 2021 Jul 26:JCO2101210. doi: 10.1200/JCO.21.01210.
    PubMed     Abstract available


  4. VROOMAN LM, Blonquist TM, Stevenson KE, Supko JG, et al
    Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
    J Clin Oncol. 2021 Jul 6:JCO2003692. doi: 10.1200/JCO.20.03692.
    PubMed     Abstract available


    June 2021
  5. DESAI PM, Brown J, Gill S, Solh MM, et al
    Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2001739. doi: 10.1200/JCO.20.01739.
    PubMed     Abstract available


  6. MYERS RM, Li Y, Barz Leahy A, Barrett DM, et al
    Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2021 Jun 22:JCO2003458. doi: 10.1200/JCO.20.03458.
    PubMed     Abstract available


  7. WEI AH, Roboz GJ, Kantarjian HM
    Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia.
    J Clin Oncol. 2021 Jun 4:JCO2100080. doi: 10.1200/JCO.21.00080.
    PubMed    


  8. ZHENG H, Jiang H, Hu S, Liao N, et al
    Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
    J Clin Oncol. 2021 Jun 2:JCO2003096. doi: 10.1200/JCO.20.03096.
    PubMed     Abstract available


    May 2021
  9. SHORT NJ, Tallman MS, Pollyea DA, Ravandi F, et al
    Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
    J Clin Oncol. 2021 May 27:JCO2100067. doi: 10.1200/JCO.21.00067.
    PubMed    


  10. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2021 May 27:JCO2003736. doi: 10.1200/JCO.20.03736.
    PubMed     Abstract available


    April 2021
  11. VAN DER PLAS E, Modi AJ, Li CK, Krull KR, et al
    Cognitive Impairment in Survivors of Pediatric Acute Lymphoblastic Leukemia Treated With Chemotherapy Only.
    J Clin Oncol. 2021 Apr 22:JCO2002322. doi: 10.1200/JCO.20.02322.
    PubMed    


    March 2021
  12. MATTANO LA JR, Devidas M, Maloney KW, Wang C, et al
    Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
    J Clin Oncol. 2021 Mar 19:JCO2002370. doi: 10.1200/JCO.20.02370.
    PubMed     Abstract available


    February 2021
  13. CLUZEAU T, Sebert M, Rahme R, Cuzzubbo S, et al
    Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM).
    J Clin Oncol. 2021 Feb 18:JCO2002342. doi: 10.1200/JCO.20.02342.
    PubMed     Abstract available


    January 2021
  14. AGRAWAL AK, Michlitsch J, Golden C, Hastings CA, et al
    Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?
    J Clin Oncol. 2021 Jan 14:JCO2002973. doi: 10.1200/JCO.20.02973.
    PubMed    


  15. LUSSANA F, Gritti G, Rambaldi A
    Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    J Clin Oncol. 2021 Jan 12:JCO2001564. doi: 10.1200/JCO.20.01564.
    PubMed    


  16. O'NEILL AT, Chakraverty R
    Graft Versus Leukemia: Current Status and Future Perspectives.
    J Clin Oncol. 2021 Jan 12:JCO2001801. doi: 10.1200/JCO.20.01801.
    PubMed     Abstract available


  17. KHALDOYANIDI S, Nagorsen D, Stein A, Ossenkoppele G, et al
    Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
    J Clin Oncol. 2021 Jan 12:JCO2000475. doi: 10.1200/JCO.20.00475.
    PubMed    


  18. KADAUKE S, Myers RM, Li Y, Aplenc R, et al
    Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
    J Clin Oncol. 2021 Jan 8:JCO2002477. doi: 10.1200/JCO.20.02477.
    PubMed     Abstract available


  19. LUGER SM
    Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark.
    J Clin Oncol. 2021 Jan 7:JCO2003142. doi: 10.1200/JCO.20.03142.
    PubMed     Abstract available


  20. ANGIOLILLO AL, Schore RJ, Kairalla JA, Devidas M, et al
    Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.
    J Clin Oncol. 2021 Jan 7:JCO2000494. doi: 10.1200/JCO.20.00494.
    PubMed     Abstract available


  21. STUTTERHEIM J, van der Sluis IM, de Lorenzo P, Alten J, et al
    Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2021 Jan 6:JCO2002333. doi: 10.1200/JCO.20.02333.
    PubMed     Abstract available


    December 2020
  22. CRADDOCK C, Jackson A, Loke J, Siddique S, et al
    Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Dec 29:JCO2002308. doi: 10.1200/JCO.20.02308.
    PubMed     Abstract available


  23. BURNETT AK, Russell NH, Hills RK, Knapper S, et al
    Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
    J Clin Oncol. 2020 Dec 23:JCO2001170. doi: 10.1200/JCO.20.01170.
    PubMed     Abstract available


  24. GAO L, Zhang Y, Wang S, Kong P, et al
    Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
    J Clin Oncol. 2020;38:4249-4259.
    PubMed     Abstract available


  25. PALMIERI R, Othus M, Halpern AB, Percival MM, et al
    Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
    J Clin Oncol. 2020;38:4163-4174.
    PubMed     Abstract available


    October 2020
  26. DINARDO CD, Stein AS, Stein EM, Fathi AT, et al
    Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Oct 29:JCO2001632. doi: 10.1200/JCO.20.01632.
    PubMed     Abstract available


  27. SALAMERO O, Montesinos P, Willekens C, Perez-Simon JA, et al
    First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Oct 14:JCO1903250. doi: 10.1200/JCO.19.03250.
    PubMed     Abstract available


  28. STILGENBAUER S
    Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition.
    J Clin Oncol. 2020 Oct 13:JCO2002685. doi: 10.1200/JCO.20.02685.
    PubMed    


  29. AHN IE, Tian X, Ipe D, Cheng M, et al
    Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
    J Clin Oncol. 2020 Oct 7:JCO2000979. doi: 10.1200/JCO.20.00979.
    PubMed     Abstract available


    September 2020
  30. KATER AP, Wu JQ, Kipps T, Eichhorst B, et al
    Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    J Clin Oncol. 2020 Sep 28:JCO2000948. doi: 10.1200/JCO.20.00948.
    PubMed     Abstract available


  31. LEHRNBECHER T, Fisher BT, Phillips B, Beauchemin M, et al
    Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.
    J Clin Oncol. 2020;38:3205-3216.
    PubMed     Abstract available


  32. STEPHENS DM, Byrd JC
    Next-Generation Bruton Tyrosine Kinase Inhibitors.
    J Clin Oncol. 2020;38:2937-2940.
    PubMed    


    August 2020
  33. DUNSMORE KP, Winter SS, Devidas M, Wood BL, et al
    Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2020 Aug 19:JCO2000256. doi: 10.1200/JCO.20.00256.
    PubMed     Abstract available


  34. ROGERS KA, Huang Y, Ruppert AS, Abruzzo LV, et al
    Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 Aug 14:JCO2000491. doi: 10.1200/JCO.20.00491.
    PubMed     Abstract available


  35. MELCHIONE C
    Journal Honors Rahul S. Vedula, MD, As Recipient of the 2020 Journal of Clinical Oncology Young Investigator Award.
    J Clin Oncol. 2020;38:2601-2602.
    PubMed    


    July 2020
  36. OSSENKOPPELE G, Vyas P
    BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML.
    J Clin Oncol. 2020 Jul 30:JCO2001788. doi: 10.1200/JCO.20.01788.
    PubMed    


  37. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed     Abstract available


  38. KROGER N
    Preventing Graft-Versus-Host Disease Without Losing Graft-Versus-Leukemia Effect After Allogeneic Stem-Cell Transplantation.
    J Clin Oncol. 2020 Jul 24:JCO2001756. doi: 10.1200/JCO.20.01756.
    PubMed    


  39. DIXON SB, Chen Y, Yasui Y, Pui CH, et al
    Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2020 Jul 24:JCO2000493. doi: 10.1200/JCO.20.00493.
    PubMed     Abstract available


  40. CHUA CC, Roberts AW, Reynolds J, Fong CY, et al
    Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
    J Clin Oncol. 2020 Jul 20:JCO2000572. doi: 10.1200/JCO.20.00572.
    PubMed     Abstract available


  41. BURCHERT A, Bug G, Fritz LV, Finke J, et al
    Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
    J Clin Oncol. 2020 Jul 16:JCO1903345. doi: 10.1200/JCO.19.03345.
    PubMed     Abstract available


    June 2020
  42. HAYASHI RJ, Winter SS, Dunsmore KP, Devidas M, et al
    Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    J Clin Oncol. 2020 Jun 17:JCO2000531. doi: 10.1200/JCO.20.00531.
    PubMed     Abstract available


  43. SHAH NN, Highfill SL, Shalabi H, Yates B, et al
    CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
    J Clin Oncol. 2020;38:1938-1950.
    PubMed     Abstract available


  44. SALZER WL, Burke MJ, Devidas M, Dai Y, et al
    Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.
    J Clin Oncol. 2020 Jun 4:JCO1902892. doi: 10.1200/JCO.19.02892.
    PubMed     Abstract available


    May 2020
  45. GHIA P, Pluta A, Wach M, Lysak D, et al
    ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 May 27:JCO1903355. doi: 10.1200/JCO.19.03355.
    PubMed     Abstract available


  46. COOPER TM, Absalon MJ, Alonzo TA, Gerbing RB, et al
    Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 May 13:JCO1903306. doi: 10.1200/JCO.19.03306.
    PubMed     Abstract available


    April 2020
  47. GETZ KD, Sung L, Alonzo TA, Leger KJ, et al
    Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 Apr 28:JCO1902856. doi: 10.1200/JCO.19.02856.
    PubMed     Abstract available


  48. LADAS EJ, Blonquist TM, Puligandla M, Orjuela M, et al
    Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort.
    J Clin Oncol. 2020 Apr 24:JCO1902555. doi: 10.1200/JCO.19.02555.
    PubMed     Abstract available


  49. FREY NV, Gill S, Hexner EO, Schuster S, et al
    Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2020 Apr 16:JCO1903237. doi: 10.1200/JCO.19.03237.
    PubMed     Abstract available


  50. GUPTA S, Wang C, Raetz EA, Schore R, et al
    Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2020 Apr 10:JCO1903024. doi: 10.1200/JCO.19.03024.
    PubMed     Abstract available


    March 2020
  51. PYZER AR
    Pigeon English.
    J Clin Oncol. 2020;38:841-842.
    PubMed    


  52. FREEMAN S, Craddock C
    Less Is Not Necessarily More: Toward a Rational Selection of the Conditioning Regimen in Acute Myeloid Leukemia.
    J Clin Oncol. 2020 Mar 2:JCO1903161. doi: 10.1200/JCO.19.03161.
    PubMed    


    February 2020
  53. CHIHARA D, Arons E, Stetler-Stevenson M, Yuan CM, et al
    Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
    J Clin Oncol. 2020 Feb 28:JCO1902250. doi: 10.1200/JCO.19.02250.
    PubMed     Abstract available


  54. WHITTINGTON MD, McQueen RB, Campbell JD
    Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications.
    J Clin Oncol. 2020;38:359-366.
    PubMed    


    January 2020
  55. KLOOS RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, et al
    Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2020 Jan 10:JCO1902292. doi: 10.1200/JCO.19.02292.
    PubMed     Abstract available


    December 2019
  56. DAO KT, Gotlib J, Deininger MMN, Oh ST, et al
    Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    J Clin Oncol. 2019 Dec 27:JCO1900895. doi: 10.1200/JCO.19.00895.
    PubMed     Abstract available


  57. HOURIGAN CS, Dillon LW, Gui G, Logan BR, et al
    Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
    J Clin Oncol. 2019 Dec 20:JCO1903011. doi: 10.1200/JCO.19.03011.
    PubMed     Abstract available


  58. SCHLENK RF, Paschka P, Krzykalla J, Weber D, et al
    Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.
    J Clin Oncol. 2019 Dec 18:JCO1901406. doi: 10.1200/JCO.19.01406.
    PubMed     Abstract available


  59. MALONEY KW, Devidas M, Wang C, Mattano LA, et al
    Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
    J Clin Oncol. 2019 Dec 11:JCO1901086. doi: 10.1200/JCO.19.01086.
    PubMed     Abstract available


  60. FREY NV, Shaw PA, Hexner EO, Pequignot E, et al
    Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2019 Dec 9:JCO1901892. doi: 10.1200/JCO.19.01892.
    PubMed     Abstract available


  61. LUBBERT M, Grishina O, Schmoor C, Schlenk RF, et al
    Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial.
    J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053.
    PubMed     Abstract available


    November 2019
  62. RANK CU, Wolthers BO, Grell K, Albertsen BK, et al
    Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
    J Clin Oncol. 2019 Nov 26:JCO1902208. doi: 10.1200/JCO.19.02208.
    PubMed     Abstract available


    October 2019
  63. JEHA S, Pei D, Choi J, Cheng C, et al
    Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.
    J Clin Oncol. 2019 Oct 28:JCO1901692. doi: 10.1200/JCO.19.01692.
    PubMed     Abstract available


  64. ECKERT C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, et al
    Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
    J Clin Oncol. 2019 Oct 23:JCO1901694. doi: 10.1200/JCO.19.01694.
    PubMed     Abstract available


    August 2019
  65. WOYACH JA
    Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?
    J Clin Oncol. 2019 Aug 28:JCO1901718. doi: 10.1200/JCO.19.01718.
    PubMed    


  66. ANGENENDT L, Rollig C, Montesinos P, Martinez-Cuadron D, et al
    Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.
    J Clin Oncol. 2019 Aug 20:JCO1900416. doi: 10.1200/JCO.19.00416.
    PubMed     Abstract available


  67. GUERCIO BJ, Zhang S, Ou FS, Venook AP, et al
    Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
    J Clin Oncol. 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019.
    PubMed     Abstract available


  68. PELLAND-MARCOTTE MC, Pole JD, Hwee J, Sutradhar R, et al
    Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data.
    J Clin Oncol. 2019 Aug 8:JCO1900570. doi: 10.1200/JCO.19.00570.
    PubMed     Abstract available


    July 2019
  69. HILLMEN P, Rawstron AC, Brock K, Munoz-Vicente S, et al
    Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    J Clin Oncol. 2019 Jul 11:JCO1900894. doi: 10.1200/JCO.19.00894.
    PubMed     Abstract available


  70. PIETERS R, De Lorenzo P, Ancliffe P, Aversa LA, et al
    Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    J Clin Oncol. 2019 Jul 8:JCO1900261. doi: 10.1200/JCO.19.00261.
    PubMed     Abstract available


    June 2019
  71. RUBNITZ JE, Lacayo NJ, Inaba H, Heym K, et al
    Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2019 Jun 27:JCO1900327. doi: 10.1200/JCO.19.00327.
    PubMed     Abstract available


  72. HAMILTON KV, Maese L, Marron JM, Pulsipher MA, et al
    Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?
    J Clin Oncol. 2019 Jun 6:JCO1900181. doi: 10.1200/JCO.19.00181.
    PubMed    


    May 2019
  73. SAVONA MR, Wei AH
    Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia.
    J Clin Oncol. 2019 May 21:JCO1900400. doi: 10.1200/JCO.19.00400.
    PubMed    


  74. HUNGER SP
    More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2019 May 14:JCO1900889. doi: 10.1200/JCO.19.00889.
    PubMed    


  75. GRAFF SL
    The Cattle Don't Care.
    J Clin Oncol. 2019;37:1136-1138.
    PubMed    


    April 2019
  76. SHARMAN JP, Coutre SE, Furman RR, Cheson BD, et al
    Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2019 Apr 17:JCO1801460. doi: 10.1200/JCO.18.01460.
    PubMed     Abstract available


    March 2019
  77. WEI AH, Strickland SA Jr, Hou JZ, Fiedler W, et al
    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    J Clin Oncol. 2019 Mar 20:JCO1801600. doi: 10.1200/JCO.18.01600.
    PubMed     Abstract available


    February 2019
  78. BURKE MJ
    Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2019 Feb 22:JCO1900143. doi: 10.1200/JCO.19.00143.
    PubMed    


  79. MCNEER JL, Devidas M, Dai Y, Carroll AJ, et al
    Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.
    J Clin Oncol. 2019 Feb 11:JCO1800884. doi: 10.1200/JCO.18.00884.
    PubMed     Abstract available


    January 2019
  80. PUI CH, Rebora P, Schrappe M, Attarbaschi A, et al
    Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.
    J Clin Oncol. 2019 Jan 18:JCO1800822. doi: 10.1200/JCO.18.00822.
    PubMed     Abstract available


  81. COOK LB, Fuji S, Hermine O, Bazarbachi A, et al
    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
    J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501.
    PubMed     Abstract available


  82. CRADDOCK C, Slade D, De Santo C, Wheat R, et al
    Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.
    J Clin Oncol. 2019 Jan 17:JCO1800889. doi: 10.1200/JCO.18.00889.
    PubMed     Abstract available


  83. CERVEIRA N, Almeida A
    Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy.
    J Clin Oncol. 2019;37:89-90.
    PubMed    


  84. BERMAN E, Druker BJ, Burwick R
    Reply to N. Cerveira et al.
    J Clin Oncol. 2019;37:90-91.
    PubMed    


  85. GETZ KD, Sung L, Ky B, Gerbing RB, et al
    Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
    J Clin Oncol. 2019;37:12-21.
    PubMed     Abstract available


    December 2018
  86. KATER AP, Seymour JF, Hillmen P, Eichhorst B, et al
    Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    J Clin Oncol. 2018 Dec 3:JCO1801580. doi: 10.1200/JCO.18.01580.
    PubMed     Abstract available


  87. DE HAAS V, Ismaila N, Advani A, Arber DA, et al
    Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline.
    J Clin Oncol. 2018 Dec 3:JCO1801468. doi: 10.1200/JCO.18.01468.
    PubMed     Abstract available


    November 2018
  88. ARMENIAN SH, Ehrhardt MJ
    Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes.
    J Clin Oncol. 2018 Nov 13:JCO1801421. doi: 10.1200/JCO.18.01421.
    PubMed     Abstract available


    October 2018
  89. CARRAWAY HE
    Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter.
    J Clin Oncol. 2018 Oct 2:JCO2018793539. doi: 10.1200/JCO.2018.79.3539.
    PubMed    


  90. FLOWERS CR, Ramsey SD
    What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
    J Clin Oncol. 2018 Oct 2:JCO2018793570. doi: 10.1200/JCO.2018.79.3570.
    PubMed    


    September 2018
  91. BASSAN R, Bourquin JP, DeAngelo DJ, Chiaretti S, et al
    New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2018 Sep 21:JCO2017773648. doi: 10.1200/JCO.2017.77.3648.
    PubMed     Abstract available


  92. LIN JK, Lerman BJ, Barnes JI, Boursiquot BC, et al
    Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2018 Sep 13:JCO2018790642. doi: 10.1200/JCO.2018.79.0642.
    PubMed     Abstract available


    August 2018
  93. WINTER SS, Dunsmore KP, Devidas M, Wood BL, et al
    Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    J Clin Oncol. 2018 Aug 23:JCO2018777250. doi: 10.1200/JCO.2018.77.7250.
    PubMed     Abstract available


    July 2018
  94. YEOH AEJ, Lu Y, Chin WHN, Chiew EKH, et al
    Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
    J Clin Oncol. 2018 Jul 25:JCO2018783050. doi: 10.1200/JCO.2018.78.3050.
    PubMed     Abstract available


  95. LANCET JE, Uy GL, Cortes JE, Newell LF, et al
    CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    J Clin Oncol. 2018 Jul 19:JCO2017776112. doi: 10.1200/JCO.2017.77.6112.
    PubMed     Abstract available


    June 2018
  96. HUGUET F, Chevret S, Leguay T, Thomas X, et al
    Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
    J Clin Oncol. 2018 Jun 4:JCO2017768192. doi: 10.1200/JCO.2017.76.8192.
    PubMed     Abstract available


    May 2018
  97. ROSS DM, Burbury KL, Grigg AP, Hughes TP, et al
    Management of Pregnancy in Women With Chronic Myeloid Leukemia.
    J Clin Oncol. 2018 May 31:JCO2018786137. doi: 10.1200/JCO.2018.78.6137.
    PubMed    


  98. VAREDI M, Lu L, Howell CR, Partin RE, et al
    Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2018 May 29:JCO2017767871. doi: 10.1200/JCO.2017.76.7871.
    PubMed     Abstract available


  99. SLAYTON WB, Schultz KR, Kairalla JA, Devidas M, et al
    Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
    J Clin Oncol. 2018 May 29:JCO2017767228. doi: 10.1200/JCO.2017.76.7228.
    PubMed     Abstract available


  100. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed    


  101. FISHER R
    Questionable Relevance of Leukemia Risk After Radioiodine Ablation of Thyroid Cancer.
    J Clin Oncol. 2018 May 3:JCO2018781534. doi: 10.1200/JCO.2018.78.1534.
    PubMed    


  102. PICCARDO A, Puntoni M, Verburg FA, Luster M, et al
    Power of Absolute Values to Avoid Data Misinterpretations: The Case of Radioiodine-Induced Leukemia and Myelodysplasia.
    J Clin Oncol. 2018 May 3:JCO2018777318. doi: 10.1200/JCO.2018.77.7318.
    PubMed    


  103. STILGENBAUER S, Eichhorst B, Schetelig J, Hillmen P, et al
    Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
    J Clin Oncol. 2018 May 1:JCO2017766840. doi: 10.1200/JCO.2017.76.6840.
    PubMed     Abstract available


    April 2018
  104. MORITA K, Kantarjian HM, Wang F, Yan Y, et al
    Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
    J Clin Oncol. 2018 Apr 27:JCO2017776757. doi: 10.1200/JCO.2017.77.6757.
    PubMed     Abstract available


  105. WALTER RB
    Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?
    J Clin Oncol. 2018 Apr 6:JCO2018783266. doi: 10.1200/JCO.2018.78.3266.
    PubMed    


    March 2018
  106. FREEMAN SD, Hills RK, Virgo P, Khan N, et al
    Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    J Clin Oncol. 2018 Mar 30:JCO2017763425. doi: 10.1200/JCO.2017.76.3425.
    PubMed     Abstract available


  107. GORE L, Kearns PR, de Martino Lee ML, De Souza CA, et al
    Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    J Clin Oncol. 2018 Mar 2:JCO2017759597. doi: 10.1200/JCO.2017.75.9597.
    PubMed     Abstract available


  108. STANULLA M, Dagdan E, Zaliova M, Moricke A, et al
    IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2018 Mar 2:JCO2017743617. doi: 10.1200/JCO.2017.74.3617.
    PubMed     Abstract available


    February 2018
  109. BERMAN E, Druker BJ, Burwick R
    Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.
    J Clin Oncol. 2018 Feb 15:JCO2017772574. doi: 10.1200/JCO.2017.77.2574.
    PubMed    


  110. BHAYADIA R, Krowiorz K, Haetscher N, Jammal R, et al
    Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
    J Clin Oncol. 2018 Feb 12:JCO2017752204. doi: 10.1200/JCO.2017.75.2204.
    PubMed     Abstract available


    January 2018
  111. SAKAMOTO K, Imamura T, Kihira K, Suzuki K, et al
    Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group.
    J Clin Oncol. 2018 Jan 23:JCO2017755066. doi: 10.1200/JCO.2017.75.5066.
    PubMed     Abstract available


  112. QIAN M, Cao X, Devidas M, Yang W, et al
    TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
    J Clin Oncol. 2018 Jan 4:JCO2017755215. doi: 10.1200/JCO.2017.75.5215.
    PubMed     Abstract available


    December 2017
  113. SOIFFER RJ, Kim HT, McGuirk J, Horwitz ME, et al
    Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplanta
    J Clin Oncol. 2017;35:4003-4011.
    PubMed     Abstract available


  114. SHAH NP
    Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.
    J Clin Oncol. 2017 Dec 5:JCO2017754663. doi: 10.1200/JCO.2017.75.4663.
    PubMed     Abstract available


    November 2017
  115. SCHRAPPE M, Bleckmann K, Zimmermann M, Biondi A, et al
    Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
    J Clin Oncol. 2017 Nov 17:JCO2017744946. doi: 10.1200/JCO.2017.74.4946.
    PubMed     Abstract available


  116. HUNGER SP
    Integrated Risk Stratification Using Minimal Residual Disease and Sentinel Genetic Alterations in Pediatric Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2017 Nov 13:JCO2017760504. doi: 10.1200/JCO.2017.76.0504.
    PubMed    


  117. O'CONNOR D, Enshaei A, Bartram J, Hancock J, et al
    Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2017 Nov 13:JCO2017740449. doi: 10.1200/JCO.2017.74.0449.
    PubMed     Abstract available


  118. OPAT S, Hawkes EA
    Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support.
    J Clin Oncol. 2017 Nov 3:JCO2017754721. doi: 10.1200/JCO.2017.75.4721.
    PubMed    


  119. CORTES JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, et al
    Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    J Clin Oncol. 2017 Nov 1:JCO2017747162. doi: 10.1200/JCO.2017.74.7162.
    PubMed     Abstract available


    October 2017
  120. LIM EL, Trinh DL, Ries RE, Wang J, et al
    MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
    J Clin Oncol. 2017 Oct 25:JCO2017747451. doi: 10.1200/JCO.2017.74.7451.
    PubMed     Abstract available


    September 2017
  121. OSTGARD LSG, Norgaard M, Medeiros BC, Friis LS, et al
    Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.
    J Clin Oncol. 2017 Sep 11:JCO2017736728. doi: 10.1200/JCO.2017.73.6728.
    PubMed     Abstract available


    August 2017
  122. WANG R, Zeidan AM, Halene S, Xu X, et al
    Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.
    J Clin Oncol. 2017 Aug 7:JCO2017727149. doi: 10.1200/JCO.2017.72.7149.
    PubMed     Abstract available


  123. KUTNY MA, Alonzo TA, Gerbing RB, Wang YC, et al
    Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
    J Clin Oncol. 2017 Aug 2:JCO2016716183. doi: 10.1200/JCO.2016.71.6183.
    PubMed     Abstract available


    July 2017
  124. BROWN JR, Kay NE
    Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017 Jul 25:JCO2017726810. doi: 10.1200/JCO.2017.72.6810.
    PubMed    


  125. TURTLE CJ, Hay KA, Hanafi LA, Li D, et al
    Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    J Clin Oncol. 2017 Jul 17:JCO2017728519. doi: 10.1200/JCO.2017.72.8519.
    PubMed     Abstract available


  126. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Abstract available


  127. HARDY KK, Embry L, Kairalla JA, Helian S, et al
    Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 Jul 3:JCO2016717587. doi: 10.1200/JCO.2016.71.7587.
    PubMed     Abstract available


  128. KROGER N, Iacobelli S, Franke GN, Platzbecker U, et al
    Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
    J Clin Oncol. 2017;35:2157-2164.
    PubMed     Abstract available


    June 2017
  129. LEONARD JP, Martin P, Roboz GJ
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    J Clin Oncol. 2017 Jun 27:JCO2017726745. doi: 10.1200/JCO.2017.72.6745.
    PubMed     Abstract available


  130. LAMBA JK, Chauhan L, Shin M, Loken MR, et al
    CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    J Clin Oncol. 2017 Jun 23:JCO2016712513. doi: 10.1200/JCO.2016.71.2513.
    PubMed     Abstract available


  131. LEE JH, Kim H, Joo YD, Lee WS, et al
    Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2017 Jun 20:JCO2017728618. doi: 10.1200/JCO.2017.72.8618.
    PubMed     Abstract available


  132. BOND J, Graux C, Lhermitte L, Lara D, et al
    Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.
    J Clin Oncol. 2017 Jun 12:JCO2016718585. doi: 10.1200/JCO.2016.71.8585.
    PubMed     Abstract available


  133. NABHAN C, Mato AR
    Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.
    J Clin Oncol. 2017;35:1863-1864.
    PubMed    


    May 2017
  134. WINICK N, Devidas M, Chen S, Maloney K, et al
    Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017 May 23:JCO2016714774. doi: 10.1200/JCO.2016.71.4774.
    PubMed     Abstract available


  135. RITCHIE EK, Guerin A, Wolff J, Joseph G, et al
    Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.
    J Clin Oncol. 2017;35:1744-1745.
    PubMed    


  136. BOUDREAU JE, Giglio F, Gooley TA, Stevenson PA, et al
    KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    J Clin Oncol. 2017 May 18:JCO2016707059. doi: 10.1200/JCO.2016.70.7059.
    PubMed     Abstract available


  137. PARK S, Hamel JF, Toma A, Kelaidi C, et al
    Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    J Clin Oncol. 2017;35:1591-1597.
    PubMed     Abstract available


  138. SEKERES MA, Othus M, List AF, Odenike O, et al
    Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
    J Clin Oncol. 2017 May 9:JCO2015662510. doi: 10.1200/JCO.2015.66.2510.
    PubMed     Abstract available


    April 2017
  139. SCOTT BL, Pasquini MC, Logan BR, Wu J, et al
    Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    J Clin Oncol. 2017;35:1154-1161.
    PubMed     Abstract available


  140. BRADSTOCK KF, Link E, Di Iulio J, Szer J, et al
    Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
    J Clin Oncol. 2017 Apr 3:JCO2016706374. doi: 10.1200/JCO.2016.70.6374.
    PubMed     Abstract available


  141. ADRA N, Abonour R, Althouse SK, Albany C, et al
    High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
    J Clin Oncol. 2017;35:1096-1102.
    PubMed     Abstract available


    March 2017
  142. MARTINELLI G, Boissel N, Chevallier P, Ottmann O, et al
    Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter St
    J Clin Oncol. 2017 Mar 29:JCO2016693531. doi: 10.1200/JCO.2016.69.3531.
    PubMed     Abstract available


  143. LANDIER W, Hageman L, Chen Y, Kornegay N, et al
    Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
    J Clin Oncol. 2017 Mar 24:JCO2016717579. doi: 10.1200/JCO.2016.71.7579.
    PubMed     Abstract available


    February 2017
  144. WOYACH JA, Ruppert AS, Guinn D, Lehman A, et al
    BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2017 Feb 13:JCO2016702282. doi: 10.1200/JCO.2016.70.2282.
    PubMed     Abstract available


  145. HOFFMAN KR
    How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?
    J Clin Oncol. 2017;35:567.
    PubMed    


    January 2017
  146. GIBSON CJ, Lindsley RC, Tchekmedyian V, Mar BG, et al
    Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
    J Clin Oncol. 2017 Jan 9:JCO2016716712.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: